anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the field of immunology, and relates to a single-domain antibody for resisting CD155 and application thereof. The single domain antibody is composed of a heavy chain, wherein the heavy chain comprises a heavy chain CDR1 shown in any one of SEQ ID NO. 25-SEQ ID NO. 29, a heavy chain CDR2 shown in any one of SEQ ID NO. 30-SEQ ID NO. 32 and a heavy chain CDR3 shown in any one of SEQ ID NO. 33-SEQ ID NO. 37. Compared with the prior art, the invention has the beneficial effects that: the invention uses biological gene engineering technology to screen out the single domain antibody specific to CD155, which has better affinity.
The present invention relates to a method for preparing ginseng, tuckahoe and white atractylodes rhizome particles. Volatile oil is extracted from villous amomum fruits; medical dregs together with ginseng and white atractylodes rhizomes are added with 95% ethanol of four-time quantity to be marinated for 24 hours; the mixed substances are filtered after hot reflux for three hours; ethanol is recovered from the filtered solution; an ethanol extract is obtained after the ethanol is concentrated. Medical dregs are then added with 50% ethanol of four-time quantity, and are filtered via hot reflux for three hours; ethanol is recovered from the filtered solution to be concentrated for obtaining an ethanol extract; medical dregs are spare. Coix seed, lotus seed, white hyacinth bean, platycodon root, liquorice and tuckahoe are added with water of eight-time quantity to be boiled for two hours, and then are filtered; the medical dregs and the spare dregs after the ethanol is extracted are added with water of eight-time quantity to be jointly boiled for 1.5 hours and then to be filtered; the two filtered solutions and water solution after distillation are merged and are filtered; when the filtered solutions are concentrated, the ethanol extracts are added and are continuously concentrated into clear paste. Chinese yam is pulverized and sieved and then is added in the paste to be dried and pulverized; one part of the powdered medicine and 0.4 part of powdered sugar are taken to be uniformly mixed, and are granulated by 70% ethanol; the volatile oil of villous amomum fruits are filled to be uniformly mixed. The granules prepared by the method of the present invention have the advantages of little dosage, good mouth feel, high bioavailability, convenient taking and high stability.
Neurological injuries remain a major concern following coronary artery bypass grafting (CABG) that offset survival benefit of CABG over percutaneous coronary interventions. Among numerous efforts to combat this issue, is off-pump CABG (OPCABG) that obviates the need for extracorporeal circulation and is associated with improved outcomes. The objective of this study is to examine whether the neuroprotective effect of OPCABG can be further pronounced by the use of two state-of-the-art operating techniques.

In this randomised, controlled, investigator and patient blinded single center superiority trial with three parallel arms a total of 360 patients will be recruited. They will be allocated in a 1:1:1 ratio to two treatment and one control arms. Treatment arms undergoing either aortic no-touch OPCABG or OPCABG with a partial clamp applying carbon dioxide surgical field flooding will be compared against control arm undergoing OPCABG. The primary endpoint will be the appearance of new lesions on control brain magnetic resonance imaging 3 days after surgery. Secondary endpoints will include the prevalence of new focal neurological deficits in the first 7 days after surgery, the occurrence of postoperative cognitive dysfunction at either 1 week or 3 months after surgery and the incidence of delirium in the first 7 days after surgery. Data will be analysed on intention-to-treat principles and a per protocol basis.
A bioactive material is made using fibroin solutions and suspensions that can be used alone or as a composite with particles such as core/shell particles. The material is designed to support the constructions, repair, regeneration or augmentation of bone and other tissues of the body. The solutions and suspensions can be loaded with core/shell-type particles comprising inorganic core materials that are coated with biodegradable polymers with an outer coating of a calcium phosphate precursor. The fibroin solutions, suspensions, and composites can be injected to fill cavities or to replace missing tissue. After injection, the materials can produce a scaffold capable of promoting tissue regeneration while degrading. The degradation of the particles, when present, can generate additional porosity within the scaffold and release other compounds in a controlled manner to enhance growth and activation of the cells necessary for tissue repair. The ability to inject the fibroin solutions, suspensions and composites can reduce the need for many types of surgical procedures that are used to replace or repair bone and other tissues.
Transaction-based behavioral profiling, whereby the entity to be profiled is represented by a stream of transactions, is required in a variety of data mining and predictive modeling applications. An approach is described for assessing inconsistency in the activity of an entity, as a way of detecting fraud and abuse, using service-code information available on each transaction. Inconsistency is based on the concept that certain service-codes naturally co-occur more than do others. An assessment is made of activity consistency looking at the overall activity of an individual entity, as well as looking at the interaction of entities. Several approaches for measuring consistency are provided, including one inspired by latent semantic analysis as used in text analysis. While the description is in the context of fraud detection in healthcare, the techniques are relevant to application in other industries and for purposes other than fraud detection.
Previous studies reported that a mild, non-protein-denaturing, fever-like temperature increase induced the unfolded protein response (UPR) in mammalian cells. Our dSTORM super-resolution microscopy experiments revealed that the master regulator of the UPR, the IRE1 (inositol-requiring enzyme 1) protein, is clustered as a result of UPR activation in a human osteosarcoma cell line (U2OS) upon mild heat stress. Using ER thermo yellow, a temperature-sensitive fluorescent probe targeted to the endoplasmic reticulum (ER), we detected significant intracellular thermogenesis in mouse embryonic fibroblast (MEF) cells. Temperatures reached at least 8 °C higher than the external environment (40 °C), resulting in exceptionally high ER temperatures similar to those previously described for mitochondria. Mild heat-induced thermogenesis in the ER of MEF cells was likely due to the uncoupling of the Ca2+/ATPase (SERCA) pump. The high ER temperatures initiated a pronounced cytosolic heat-shock response in MEF cells, which was significantly lower in U2OS cells in which both the ER thermogenesis and SERCA pump uncoupling were absent. Our results suggest that depending on intrinsic cellular properties, mild hyperthermia-induced intracellular thermogenesis defines the cellular response mechanism and determines the outcome of hyperthermic stress.
The patient will be seen in the PH clinic and will be approached to consent and participate in the SYMPACT trial. Based on the patients in Group 1 and 3 PH and a high SYMPACT score\> 1.0 in any domain they will be randomized to receive standard care or a palliative care initial consult.
FIELD: biology. SUBSTANCE: coagulated blood is washed against plasma by physiologic salt solution, poured by 5 % solution of sodium citrate, allowed to stand within about 12 h and is then centrifuged. After complete hemolysis water is added into thus prepared precipitate and additional centrifugation is carried out. Hemolyzate is separated and poured by acetone. Thus prepared mixture is centrifuged, liquid is separated and precipitate being washed by acetone several times. Then centrifugation, filtration and drying are carried out. Thus prepared dry powder is cherry-colored. Modification of proposed preparation which has no antigen properties also may be prepared. Said process is carried out by adding concentrated hydrochloric acid into precipitate before its filtration and drying. Quantity of said acid is 0.1 of volume of acetone. Thus prepared mixture is allowed to stand within few minutes and then it is centrifuged. Thus prepared precipitate is washed several times by acetone, filtered and dried. Desired powder has slight grey color. EFFECT: improves efficiency of the method. 2 cl
BACKGROUND: The National Chest Pain Center Program (NCPCP) is a nationwide, quality enhancement program aimed at raising the standard of care for patients experiencing acute chest pain in China. The benefits of chest pain center (CPC) accreditation on acute coronary syndrome have been demonstrated. However, there is no evidence to indicate whether CPC accreditation improves outcomes for patients with acute aortic dissection (AAD).
METHODS: We conducted a retrospective observational study of patients with AAD from 1671 hospitals in China, using data from the NCPCP spanning the period from January 1, 2016 to December 31, 2022. The patients were divided into 2 groups: pre-accreditation and post-accreditation admissions. The outcomes examined included in-hospital mortality, misdiagnosis, and Stanford type A AAD surgery. Multivariate logistic regression was employed to explore the relationship between CPC accreditation and in-hospital outcomes. Furthermore, we stratified the hospitals based on their geographical location (Eastern/Central/Western regions) or administrative status (provincial/non-provincial capital areas) to assess the impact of CPC accreditation on AAD patients across various regions.
RESULTS: The analysis encompassed a total of 40,848 patients diagnosed with AAD. The post-accreditation group exhibited significantly lower rates of in-hospital mortality and misdiagnosis (12.1% vs. 16.3%, P < 0.001 and 2.9% vs. 5.4%, P < 0.001, respectively) as well as a notably higher rate of Stanford type A AAD surgery (61.1% vs. 42.1%, P < 0.001) compared with the pre-accreditation group. After adjusting for potential covariates, CPC accreditation was associated with substantially reduced risks of in-hospital mortality (adjusted OR 0.644, 95% CI 0.599-0.693) and misdiagnosis (adjusted OR 0.554, 95% CI 0.493-0.624), along with an increase in the proportion of patients undergoing Stanford type A AAD surgery (adjusted OR 1.973, 95% CI 1.797-2.165). Following CPC accreditation, there were significant reductions in in-hospital mortality across various regions, particularly in Western regions (from 21.5 to 14.1%). Moreover, CPC accreditation demonstrated a more pronounced impact on in-hospital mortality in non-provincial cities compared to provincial cities (adjusted OR 0.607 vs. 0.713).
CONCLUSION: CPC accreditation is correlated with improved management and in-hospital outcomes for patients with AAD.
Participants began administration with 25 mg ruxolitinib sustained release (SR) once daily (QD). After 8 weeks, if there was inadequate efficacy, the dose level could be titrated to 50 mg SR QD or 25 mg SR every other day (QOD) alternating with 50 mg SR QOD. At Week 16, participants transitioned to ruxolitinib 10, 15, or 20 mg immediate release (IR) orally twice daily. Participants who continued to demonstrate benefit in the opinion of the investigator could remain on ruxolitinib IR until the last participant completed Week 36 or the commercial availability of ruxolitinib IR, whichever was earlier; the dose received was based on platelet counts at the time of transition.
This is a prospective cohort pilot study at Boston Children's Hospital (BCH) that will explore the source of presumed CLABSI, which we believe may actually have multiple possible sources including MBI. We plan to enroll all inpatient children at BCH who meet the Centers for Disease Control and Prevention (CDC) definition of MBI-LCBI as well as children who meet the criteria for CLABSI without MBI. For all enrolled patients, we will collect samples from the oral cavity, respiratory tract, skin, and stool. These samples will be cultured in order to see if the same microbial species and strain(s) growing from the blood also grow from these other sites. Cultures will then have isolated colonies selected for whole-genome DNA sequencing to allow assessment of genomic diversity between body sites. Stool and blood samples will be tested for markers of MBI. All patient enrollment and sample collection will be done at BCH.
Clinical studies of photodynamic therapy (PDT) with PHOTOFRIN were conducted in patients with obstructing esophageal and endobronchial non-small-cell lung cancers (NSCLC), in patients with early-stage radiologically occult endobronchial cancer, and in patients with high-grade dysplasia (HGD) in Barrett’s esophagus (BE). In all clinical studies, the method of PDT administration was essentially identical. A course of therapy consisted of one injection of PHOTOFRIN (2 mg/kg administered as a slow intravenous infusion over 3–5 minutes) followed by up to two non-thermal applications of 630 nm laser light. Light doses of 300 J/cm of diffuser length were used in esophageal cancer. Light doses of 200 J/cm of diffuser length were used in endobronchial cancer for both palliation of obstructing cancer and treatment of superficial lesions. Light doses of 130 J/cm of diffuser length using a centering balloon for the first application and 50 J/cm of diffuser length without a centering balloon for the second application were used for HGD in BE [see Dosage and Administration ( 2.2)] . In all cases, the first application of light occurred 40–50 hours after PHOTOFRIN. 

For treatment of esophageal cancer, optional debridement of residua could be performed via endoscopy 96-120 hours after PHOTOFRIN administration, after which any residual tumor could be retreated with a second laser light application at the same light dose used for the initial treatment. Additional courses of PDT with PHOTOFRIN were allowed after 1 month, up to a maximum of 3 courses.

For treatment of endobronchial cancer, debridement of residua was performed via bronchoscopy 96-120 hours after PHOTOFRIN administration, after which any residual tumor could be retreated with a second laser light application at the same light dose used for the initial treatment. Additional courses of PDT with PHOTOFRIN were allowed after 1 month, up to a maximum of 3 courses.

For ablation of HGD in BE, a second laser light application of 50 J/cm of diffuser length without a centering balloon could be given 96-120 hours after PHOTOFRIN administration for untreated areas (“skip” areas).   
Additional courses of PDT with PHOTOFRIN were allowed after 3 months, up to a maximum of 3 courses.
A peptide interacting with members of the anti-apoptotic Bcl-2 protein family comprising a fully defined 24 amino acid sequence (SEQ ID NO. 1-6) given in the specification, or their functional variants, is new. Independent claims are included for: (1) nucleic acid sequences encoding the peptide; (2) a recombinant vector comprising the nucleic acid sequence; (3) a host cell comprising the vector; (4) a pharmaceutical composition comprising the peptide; and (5) identifying (M1) modulators of the interaction of the peptide and an anti-apoptotic Bcl-2 family member comprising: (a) contacting the peptide with an anti-apoptotic Bcl-2 family member; (b) adding the test compound; and (c) measuring the activity of the test compound which modulates interaction between the peptide and anti-apoptotic Bcl-2 family member and comparing it to a measurment taken in the absence of the test compound. ACTIVITY : Cytostatic; Apoptotic. No biological data given. MECHANISM OF ACTION : None given.
Lysyl oxidase-like 2 (LOXL2) mediates the crosslinking of extracellular collagen, reflecting qualitative changes in liver fibrosis. This study aimed to validate the utility of serum LOXL2 levels as a predictive biomarker for the development of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) infection who achieved a sustained virological response (SVR). This retrospective study included 137 patients with chronic HCV infection without history of HCC development and who achieved SVR via direct-acting antiviral therapy. Median LOXL2 levels decreased significantly after SVR achievement (pre-Tx, 2.33 ng/mL; post-Tx, 1.31 ng/mL, p < 0.001). Post-Tx LOXL2 levels, fibrosis-4 index, platelet counts, Wisteria floribunda agglutinin-positive human Mac-2 binding protein levels, and alpha-fetoprotein (AFP) levels were identified as independent predictive factors for post-SVR HCC development in the univariate analysis. The incidence of post-SVR HCC development was significantly higher in patients with post-Tx LOXL2 levels ≥ 2.08 ng/mL and AFP levels ≥ 5.0 ng/mL than in patients with elevated levels of either marker or with lower marker levels. Serum LOXL2 levels can serve as a predictive biomarker for HCC development after achieving SVR. The combination of serum LOXL2 and AFP levels provides robust risk stratification for HCC development after SVR, suggesting an enhanced surveillance strategy.
Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 1 hour on day 1, and pegfilgrastim subcutaneously on day 2. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of docetaxel, cisplatin, and pegfilgrastim, patients receive oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity.
PROBLEM TO BE SOLVED: To obtain the subject bone resorption inhibitor that inhibits bones from resorbing, can be readily utilized in the daily life, as it can be ingested safely for a long period of time, and is useful for prophylaxis and therapy of osteoporosis. SOLUTION: The objective bone resorption inhibitor is obtained by using the extract from a plant, Cassia minosides L.Var. momame Makino, as an active ingredient and is effective for the prophylaxis and/or the therapy of osteoporosis. In a preferred embodiment, the extract is obtained by the solvent extraction or the compression of the plant body, particularly extracted with a solvent selected from ethanol, water and their mixture. In another preferred embodiment, the plant bodies in an amount of 1 kg are placed in 1-50 liters of a solvent and they are allowed to stand for one day to one month at room temperature. The extract may be directly used, but in general, may be in the form of oral preparations, for example, capsules or the like or parenteral preparations, for example suppository and the like.  The daily dose of this inhibitor is 1-100 mg/kg body weight, particularly 5-2 mg/kg body weight on the dry basis.
OBJECTIVE: To describe the hyperproliferation of Elschnig pearl-type posterior capsule opacification and concurrent uveitis in two canine eyes after phacoemulsification, followed by spontaneous resolution of the Elschnig pearls.
ANIMAL STUDIED: A 10-year-old castrated male Spitz (Case 1) and a 4-year-old spayed female Bichon Frise (Case 2).
PROCEDURE: Elschnig pearls proliferating beyond the anterior capsulotomy site were observed in the right eye 10 months after bilateral diabetic cataract surgery (Case 1) and 7 months after unilateral cataract surgery (Case 2). In both cases, hyperproliferation occurred where the anterior capsule did not overlap with the intraocular lens (IOL), and was accompanied by aqueous flare. In Case 1, the pearls extended from the anterior capsule and adhered to the iris, causing focal posterior synechia. No other possible causes of uveitis were apparent.
RESULTS: Initially, uveitis severity improved after the administration of topical and systemic anti-inflammatory drugs. However, uveitis recurred when the dosage of anti-inflammatory treatment was reduced. The Elschnig pearls underwent morphological changes throughout the follow-up period. In both cases, the pearls beyond the anterior capsulotomy resolved spontaneously after 5 months. Only a few pearls remained between the IOL and posterior capsule, and no recurrence of pearl proliferation was observed at the last follow-up.
CONCLUSIONS: To the best of our knowledge, this is the first report of spontaneous Elschnig pearl regression in dogs. Lens-induced uveitis (LIU) may have been caused by anterior chamber hyperproliferative pearls. LIU associated with hyperproliferative pearls may be managed with appropriate anti-inflammatory treatment and monitoring.
PURPOSE: This study aimed to investigate the possible mechanisms by which ANGPTL4 is involved in the pathogenesis of choroidal neovascularization (CNV) and subretinal fibrosis.
METHODS: Differentially expressed genes in retinal pigmented epithelium (RPE)-choroid-sclera complex tissues from nAMD patients and control individuals were identified via the GEO database, followed by GO and KEGG analyses. A Venn diagram was used to identify EndMT-related DEGs. A logistic regression model was constructed to screen for prognostic genes. Laser-induced CNV mouse models were established and validated with FFA and OCTA. The expression of ANGPTL4 and EndMT-related markers in the RPE-choroid-sclera complex was measured via RT‒qPCR and Western blotting. TGF-β2-induced HUVECs were used as EndMT cell models, and specific siRNAs targeting ANGPTL4 (si-ANGPTL4) were designed and screened. The effects of ANGPTL4 knockdown on the migration and invasion of HUVECs were also examined. Laser-induced CNV mouse models were constructed, and an intravitreal injection of cholesterol-modified si-ANGPTL4 was used to knock down ANGPTL4. FFA, OCTA and immunofluorescence staining were used to observe CNV formation and subretinal fibrosis, and the expression of ANGPTL4 and EndMT-related markers was determined.
RESULTS: ANGPTL4 expression was significantly increased in mice with CNV and colocalized with IB4. In TGF-β2-induced EndMT, ANGPTL4 was also upregulated, and its knockdown led to the inhibition of EndMT and cell migration and invasion, while its overexpression promoted the EndMT process. ANGPTL4 knockdown reduced the formation of CNV and subretinal fibrosis in mice with CNV by suppressing EndMT.
CONCLUSIONS: ANGPTL4 may promote CNV and subretinal fibrosis through EndMT, suggesting that ANGPTL4 may be a novel potential target for nAMD therapy.
A historical control group will be matched to the estimated 1150 HeartCare group patients who complete at least two years of HeartCare surveillance use and inclusive of year 3 post-transplant clinical follow-up for outcome. The criteria for the matched controls will be based on allograft donor type, age, gender, ethnicity/race, and other clinical factors. Propensity scores will be used to perform the matching.
Cyclohexanedial-1,4 is made by catalytic dehydrogenation of cyclohexane-1,4-dimethylol in the gaseous state at a temperature between 300 DEG  and 600 DEG  C. in the presence of oxygen or an oxygen-containing gas, e.g. air, and distilling the reaction mixture so obtained.  The reaction may be effected at pressures below 100 mm. Hg, for example below 10 mm. Hg.  Typical dehydrogenation catalysts may be used including copper, silver, zinc, brass alloys, Adkins catalysts based on copper-chromite with varying additions of zinc and/or nickel and/or barium, noble metals and oxides or compounds of metals of Groups V and VI of the Periodic System such as molybdenum, vanadium or titanium. Detailed examples are given.